Invesco Pharmaceuticals ETF (NY:PJP)

123.44 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Invesco Pharmaceuticals ETF

< Previous 1 2 Next >

Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? ↗

October 11, 2026

Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.

Via The Motley Fool

Topics ETFs

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗

October 11, 2026

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

Via The Motley Fool

Topics ETFs

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Via The Motley Fool

Topics ETFs

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided ↗

July 21, 2025

Via Stocktwits

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗

September 23, 2026

XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.

Via The Motley Fool

Topics ETFs

Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits ↗

September 08, 2026

Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗

August 28, 2026

VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

Via The Motley Fool

Topics ETFs

FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? ↗

August 23, 2026

Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks.

Via The Motley Fool

Topics ETFs

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗

August 19, 2026

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

Via The Motley Fool

Topics ETFs

XPH vs PJP: Which Pharma ETF Offers Better Value ↗

August 17, 2026

State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers.

Via The Motley Fool

Topics ETFs

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? ↗

July 22, 2026

PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.

Via The Motley Fool

Topics ETFs

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗

July 20, 2026

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

Via The Motley Fool

Topics ETFs

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

July 20, 2026

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

Via The Motley Fool

Topics ETFs

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? ↗

July 08, 2026

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

Via The Motley Fool

Topics ETFs

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗

July 05, 2026

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

Via The Motley Fool

Topics ETFs Intellectual Property

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗

July 04, 2026

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

Via The Motley Fool

Topics ETFs

State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗

July 04, 2026

Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.

Via The Motley Fool

Topics ETFs

Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution? ↗

June 15, 2026

Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.

Via The Motley Fool

Topics ETFs

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗

June 05, 2026

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

Via The Motley Fool

Topics ETFs

Why Did CANF Stock Soar 40% In Pre-Market Today? ↗

March 04, 2026

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Via Stocktwits

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗

February 18, 2026

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Via Stocktwits

Topics ETFs Government

Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗

January 15, 2026

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

Via Stocktwits

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.

Via Benzinga

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.